Abstract 16641: High Dose Omega-3 Fatty Acid Supplements to Lower Triglyceride Levels in 10-19 Year-Olds
Objective: To evaluate the triglyceride (TG) lowering effect of high dose omega-3 fatty acids (FA) in hypertriglyceridemic adolescents.
Patients and Methods: One month after screening, 25 patients ages 10-19 years of age with TG levels ≥ 150 mg/dL were randomized to a 6 month double-blind placebo controlled trial of Lovaza (4 grams/day, 840 mg DHA +EPA) vs. Placebo. Study visits occurred at baseline, 3 and 6 months and included fasting lipid profile, safety labs, adverse effects assessment, anthropometrics and vascular testing.
Results: Baseline TG levels were high for the group as a whole (mean ± SD 227 ± 49). Between baseline and 3 months, TG levels declined in the Lovaza group by 54 ± 27 mg/dL (mean ± SE, p=0.02), see Figure Panel A. TG levels also declined at 3 months in the Placebo group by 34 ± 26 mg/dL; however, this decline did not reach significance (p=0.16); the Lovaza-Placebo difference was not significant (p=0.52). LDL levels increased in the Lovaza group by 14 ± 6 mg/dL (p=0.02) at 3 months but the effect was not sustained, and did not differ from Placebo. RBC membrane levels of omega-3FA (EPA + DHA) increased 1.9-fold in patients on Lovaza, indicating compliance (p<0.0001) see Figure, Panel B. There were no significant changes or between-group differences in vascular testing, blood pressure and BMI percentile, C-reactive protein or other parameters. The drug was well tolerated, without significant side effects; no one in the Lovaza group dropped out of the study.
Conclusions: High dose omega-3 FA can lower TGs, although we could not demonstrate a statistical difference between Lovaza and Placebo in this pilot study. Lovaza was well tolerated and there were no significant safety issues.
- © 2012 by American Heart Association, Inc.